Sign in Subscribe
Diseases

Impact of Donor Graft Cell Composition on Acute Myeloid Leukemia Outcomes

Strategic Insights

— 1 min read

Investigators at the University of Washington, in collaboration with the Fred Hutchinson Cancer Center, have conducted a comprehensive study to examine the impact of donor graft cell composition on post-HCT outcomes in acute myeloid leukemia (AML) patients. The research team utilized an electronic database to identify adults with AML who underwent myeloablative conditioning (MAC) HCT between 2006 and 2023. The findings suggest a non-linear relationship between CD34+ cell dose and relapse risk in AML patients, with a threshold of 5.61 x 10^6/kg beyond which the relapse risk no longer decreases.

Key Takeaways:

  • The study found a significant association between CD34+ cell dose and relapse risk in AML patients undergoing myeloablative allogeneic HCT, with a threshold of 5.61 x 10^6/kg beyond which the relapse risk no longer decreases.
  • Higher CD3+ doses were linearly associated with an increased incidence of moderate-severe chronic graft-versus-host disease (GVHD).
  • The research identified a non-linear relationship between CD34+ cell dose and relapse risk, with pre-HCT measurable residual disease (MRD) status having no significant impact on outcomes.
  • The study's findings suggest that donor graft composition impacts outcomes in adults with AML undergoing allogeneic HCT after MAC, independent of pre-HCT MRD status.
  • The research team utilized an electronic database to identify 385 adults with MDS/AML or AML who underwent MAC and received 10/10 HLA-matched sibling or unrelated donor mobilized PBSC allografts in first morphologic remission between 2006 and 2023.

Statistics:

  • The study involved 385 adults with MDS/AML or AML who underwent MAC HCT between 2006 and 2023.
  • The CD34+ cell dose threshold of 5.61 x 10^6/kg was associated with a significant decrease in relapse risk.
  • The incidence of moderate-severe chronic GVHD increased with higher CD3+ doses.
  • The study found a non-linear relationship between CD34+ cell dose and relapse risk in AML patients undergoing myeloablative allogeneic HCT.

Sources:

  • NewsRx. Reports from University of Washington Provide New Insights into Acute Myeloid Leukemia (Cd34+cell Dose, Measurable Residual Disease, and Outcome After Myeloablative Hla-matched Peripheral Blood Hematopoietic Cell Transplantation for Adults With ...). Hematology Week. August 25, 2025; p 1688.
  • Cancers. Cd34+cell Dose, Measurable Residual Disease, and Outcome After Myeloablative Hla-matched Peripheral Blood Hematopoietic Cell Transplantation for Adults With Acute Myeloid Leukemia. 2025;17(14):2323.

Read more